Kornimate/medical-research-clean huggingface dataset:
how does the spirituality of patients with type 2 diabetes influence their self-management?

Conditions: Type 2 Diabetes

Summary: this exploratory study is researching how the spirituality of a group of british patients with type 2 diabetes (t2d), impacts their approach to the self-management of their condition. bio-statistical markers will be taken from consenting participants' clinic database records. qualitative interviews will be conducted with participants, and the results analysed and interpreted, alongside their bio-statistical markers. results will be presented in healthcare peer reviewed journals and conferences, to inform clinicians how patients' self-management of their t2d is influenced by their spirituality.

patients will be recruited from diabetes clinics. the bio-statistical markers will be: include their living situation (living alone or with family/partner); date of t2d diagnosis; current age; glycated haemoglobin (hba1c) blood test; body mass index and current pharmacological therapy. this data will be collected from the diabetes clinic to contextualize the qualitative data. these measurements will reveal how well a participant is managing their t2d. the biographic narrative interpretive method (bnim) will involve interviews with eight participants. each participant will have at least 2 and possibly 3 interviews at a location of their choice. the data will undergo thematic analysis, which will be interpreted. the results will be used to encourage clinicians to consider the spirituality of people with t2d when planning their care, thus giving holistic treatment.

Eligibility criteria:
inclusion criteria: * speak english * have had t2d at least 6 months. * have read the participant information sheet, explaining this study is regarding t2d, spirituality, coping and self-management. * gives consent to access their diabetes details that are stored on a clinic database. * gives consent to recorded interviews. exclusion criteria: * not speak english. * have had t2d less than 6 months. * have read the participant information sheet, and decided they are not comfortable talking about their t2d, or spirituality, or coping or their self-management. * not consenting to data collection from clinic records. * clinic records have not been kept (e.g. is a new patient to their family doctor). * consent is withdrawn from the study (which could be any stage).
study of the radio-clinical correlation of endolymphatic hydrops

Conditions: Endolymphatic Hydrops

Summary: in patients presenting with symptoms of endolymphatic hydrops, signs of vestibular dilation are often found on mri. some patients present with these radiological signs without vestibular clinical signs, or signs other than those of hydrops. no study has yet investigated the radiological-clinical correlation of endolymphatic hydrops by selecting patients based on their imaging findings and then comparing them to the symptoms presented.


Eligibility criteria:
inclusion criteria: * adult subject (≥18 years) * subject presenting vestibular dilation on mri exclusion criteria: * subjects who have expressed opposition to the reuse of their data for scientific research purposes. * subjects under legal protection * subjects under guardianship or curatorship

Keywords: endolymphatic hydrops
prognostic models for hcc based on tumor micronecrosis

Conditions: Hepatocellular Carcinoma

Summary: the heterogeneity of hepatocellular carcinoma (hcc) leads to the unsatisfying predicting performance of current staging systems. hcc patients with pathological tumor micronecrosis have immunosuppressive microenvironment. we aimed to develop novel prognostic models by integrating micronecrosis to more precisely predict the survival of hcc patients after hepatectomy.


Eligibility criteria:
inclusion criteria: 1. pathologically diagnosed as hcc; 2. curative hepatectomy with r0 resection; 3. conserved liver function with child pugh class a or b exclusion criteria: 1. with macrovascular invasion or extrahepatic metastasis; 2. receiving other anti-tumor treatments such as tace or systemic drugs; 3. with other primary cancers; 4. incomplete follow-up data; 5. without sufficient formalin-fixed, paraffin-embedded (ffpe) specimens for micronecrosis evaluation

Keywords: hepatocellular carcinoma tumor micronecrosis nomogram
semirecumbent position by mechanical ventilation

Conditions: Mechanical Ventilation Complication; Ventilator Associated Pneumonia; Compliance, Treatment

Summary: it's based in an observational trial in mechanical ventilated patients. the investigators assess the head of bed elevation angle in the routine treatment of the unit. the investigators decide to assess the time the patient has a semirecumbent position \>35°.

a semirecumbent-bed position in mechanical ventilated patients is recommended in every international guidelines in order to avoiding ventilator associated pneumonia (vap). despite being a simple and cheap measure, the literature describe a low compliance. globally, every intensive care unit tends to use different maneuvers that help or improve compliance of this recommendation. however, there are multiple factors in daily work that hinder compliance. before taking actions, it would be convenient to know the current state of the unit. investigators aim to evaluate the quality with which the recommendation is carried out in the unit in order to maintain a semirecumbent position. to conduct the trial it will be used a device that measures continuously (every 5 minutes) the angle of the bed without giving any information to caregivers. once patients are extubated the data will be collected.

Eligibility criteria:
inclusion criteria: * every ventilated patients exclusion criteria: * patients excluded are those lower that 18 years old or neurocritical patients that require flat position.
study of nimotuzumab to treat colorectal cancer

Conditions: Advanced Colorectal Cancer

Summary: nimotuzumab is an igg1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (egfr). clinical efficacy has been shown in adult with head and neck cancer. the study assessed the safety, and efficacy of the combination of nimotuzumab administered concomitantly with chemotherapy in patients with advanced colorectal cancer.

nimotuzumab and irinotecan will be administered to the patient until disease progression or development of toxicity preclude further treatment.irinotecan will be administered once every 14 days,the dosage is 180mg/m2; nimotuzumab treatment be divided 3 levels:200mg/w,400mg/w,600mg/w,weekly.the patients'blood test and liver and renal function tests will be monitored weekly, a physical exam and reassessment of the tumor will be performed and every 6 weeks,when the total result is the cr or pr, the result of the 6th and the 12th week should be compared.

Eligibility criteria:
inclusion criteria: * informed consent form signed before performing any of the study's specific procedures. * ecog performance status 0-2. * age \> 18，both genders. * metastatic colorectal cancer confirmed by pathology, or locally advanced unresectable colorectal cancer, or postoperative recurrence and metastasis colorectal cancer * disease progression after receiving oxaliplatin ± fluorouracil in first-line treatment * at least 1 measurable lesions ,( longest diameter≥ 1 cm by spiral computed tomography (ct) scan or mri) * life expectancy more than 3 months. * k-ras is wild type * use of an effective contraceptive method for patients of both sexes when there is a risk of conception and/or pregnancy. * liver metastasis, lesions smaller than 50% of the liver; lung metastasis, lesions smaller than 30% of the lung * haemoglobin≥90g/l , granulocyte≥1.5×109/l ,wbc ≥3×109/l, platelet count≥100×109/l * tbil≤ 1.5 x uln ,alk≤ 2.5 x uln or ≤ 5uln（liver metastasis），ast and alt≤ 2.5 x uln or ≤ 5uln（liver metastasis）,creatinine ≤ 1.5 x uln * no brain metastasis exclusion criteria: * previous radiotherapy at lesions within three months * other first line chemo-agents treatment except oxaliplatin ± fluorouracil * received other anti egfr monoclonal antibody treatment * complete or incomplete intestinal obstruction * participation in other interventional clinical trials within 1 month * psychiatric disease affected cognitive ability, including brain metastasis * peripheral neuropathy lesion is more than i stage * history of serious allergic or allergy * pregnant or breast-feeding women * patients with the history of serious lung or hear disease * other malignant tumor

Keywords: nimotuzumab colorectal cancer chemotherapy
docetaxel and epirubicin as first-line therapy in treating patients with locally advanced or metastatic adenocarcinoma of the stomach

Conditions: Gastric Cancer

Summary: rationale: drugs used in chemotherapy, such as docetaxel and epirubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. giving more than one drug may kill more tumor cells. purpose: this phase ii trial is studying how well giving docetaxel together with epirubicin as first-line therapy works in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the stomach.

objectives: primary * determine the objective tumor response rate and time to tumor progression in patients with locally advanced or metastatic adenocarcinoma of the stomach treated with docetaxel and epirubicin as first-line therapy. secondary * determine the survival without local relapse and overall survival of patients treated with this regimen. * determine the tolerance to this regimen in these patients. outline: this is an open-label, multicenter study. patients receive epirubicin iv over 30 minutes and docetaxel iv over 1 hour on day 1. treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 39 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed adenocarcinoma of the stomach * locally advanced or metastatic disease * measurable disease * at least 1 unidimensionally measurable target lesion at least 2 cm in diameter * no known symptomatic brain metastases * no bone metastases patient characteristics: age * 18 to 75 performance status * ecog 0-2 life expectancy * at least 3 months hematopoietic * absolute neutrophil count at least 2,000/mm\^3 * platelet count greater than 100,000/mm\^3 hepatic * bilirubin less than 2 times normal * ast and alt no greater than 2.5 times normal * alkaline phosphatase no greater than 2.5 times normal renal * creatinine less than 1.6 mg/dl or * creatinine clearance greater than 60 ml/min cardiovascular * no serious cardiac failure within the past 12 months * no myocardial infarction within the past 12 months * no cardiac insufficiency * no angina other * not pregnant or nursing * fertile patients must use effective contraception * no uncontrolled serious infection * no significant brain or psychiatric disorders * no intolerance to cortisone or polysorbate 80 * no other prior malignancy except curatively treated basal cell skin cancer or carcinoma in situ of the cervix * no other illness or medical condition that would preclude study participation * no peripheral neuropathy greater than grade 2 prior concurrent therapy: biologic therapy * not specified chemotherapy * no prior chemotherapy endocrine therapy * not specified radiotherapy * not specified surgery * not specified other * more than 21 days since prior participation in another clinical study * no other concurrent experimental medication

Keywords: adenocarcinoma of the stomach stage iii gastric cancer stage iv gastric cancer
the diagnostic and prognostic value of presepsin in sepsis

Conditions: Septic Shock

Summary: intra-abdominal infections are a common cause of sepsis and frequently occur in intensive care unit (icu) patient. various markers such as procalcitonin, presepsin and endotoxin are used to identify patients at risk of sepsis or to guide proper treatment. no studies compared presepsin to procalcitonin and endotoxin in patients treated with by extracorporeal hemoperfusion with a polymyxin-b-adsorbing cartridge (pmx-ha).

intra-abdominal infections are a common cause of sepsis and frequently occur in intensive care unit (icu) patient. various markers such as procalcitonin, presepsin and endotoxin are used to identify patients at risk of sepsis or to guide proper treatment. particularly, endotoxin can be removed from the blood by extracorporeal hemoperfusion with a polymyxin-b-adsorbing cartridge (pmx-ha). no studies compared presepsin to procalcitonin and endotoxin in patients treated with pmx-ha. the investigators aim to evaluate the trend and prognostic value of presepsin versus procalcitonin and endotoxin in icu patients with septic shock from complicated major abdominal surgery, treated with pmx-ha.

Eligibility criteria:
inclusion criteria: * caucasian patients * patients undergoing laparoscopic major abdominal surgery exclusion criteria: * pregnancy, * organ transplantation, * palliative care * metastatic cancer * head trauma and polytrauma * coagulopathies * use of anticoagulants * neurological disease * autoimmune disease * thyroid disease.

Keywords: septic shock
impact of obesity on post-operative cognitive dysfunction: role of adipose tissue

Conditions: Obesity; Cognitive Impairment; Post-Operative Confusion

Summary: this research aims at describing the relationship between white adipose tissue inflammation and post-operative cognitive dysfunctions.the possible link between inflammatory cytokines secretions of the white adipose tissue of a surgical wound and the arising of patient's cognitive dysfunction in the post-operative course will be investigated. the hypothesis is that obese patient's inflammation of the white adipose tissue leads to cognitive dysfunction.

the postoperative cognitive dysfunctions (pocd) are characterized by delirium and cognitive impairment. the delirium is defined by an acute altered attention with a fluctuating course. the post-operative cognitive impairment involves the early alteration of different functions including memory, attention and cognitive flexibility. pocd have a major impact in patient's morbidity. they are linked to the systemic inflammation induced by the surgical wound. the systemic inflammation leads to the rupture of the brain-blood barrier and to hippocampal inflammation. as hippocampus mediates the principal cognitive functions, hippocampal inflammation leads to pocd. orthopedic and cardiac surgery are particularly concerned. obesity is growing condition in the french population. it is linked to chronic systemic inflammation and altered cognitive functions. we think that obese people may present a susceptibility to pocd because of the pre-operative systemic inflammation.

Eligibility criteria:
inclusion criteria: * patient about to receive a hip arthroplasty under general anesthesia, elective cardiac surgery with cardiopulmonary bypass, * patient with a mmse score \> or = 20(/30), * patient able to give informed consent exclusion criteria: * emergency surgery, or surgery in a septic context, * patient with a known dementia or altered mmse score (under 20)

Keywords: obesity post-operative cognitive dysfunction inflammation inflammatory cytokines
radiology consultation effectiveness

Conditions: Radiology Interventional; Spinal Injections; Back Pain

Summary: performing a consultation with the radiologist before a spinal invasive procedure serves to foster a trusting physician-patient relationship. it also provides an opportunity for the comprehensive explanation of the procedure, its aftermath, and any patient inquiries. we believe that this proactive approach has the potential to alleviate pre-procedure anxiety, thereby contributing to an enhanced overall experience of the intervention and its outcomes. despite these potential benefits, it is noteworthy that such consultations are not systematically implemented, and their impact on the intervention effictness remains unexplored in existing literature. the hypothesis is grounded in the belief that patients who perform a consultation preceding their spinal intervention are likely to witness improvements in both the overall experience of the procedure and its effectiveness.


Eligibility criteria:
inclusion criteria: * patient 18 years of age or older * referred to the imaging department for a peri-spinal injection under ct guidance. * low back pain, dorsal pain, or neck pain with an average pain intensity of ≥ 5/10 on nprs. exclusion criteria: * patient unable to read and/or write french * patient unable to condut a teleconsultation (no phone, no internet connection) * current pregnancy, breastfeeding, or lack of effective contraception for women of childbearing age * lack of consent * legally protected population: * adults protected by law (guardianship, curatorship, or judicial protection) * non-emancipated minors * individuals unable to express consent (research conducted in emergency situations) * individuals deprived of liberty (by judicial or administrative decision, or involuntary hospitalization) * not affiliated with a social security scheme or not benefiting from such a scheme * participation in another research study with an ongoing exclusion period

Keywords: consultation remote consultation radiology interventional spinal injections health care
the effect of high vs. moderate protein consumption on human health

Conditions: Weight Loss; Metabolism and Nutrition Disorder; Obesity

Summary: the study will be conducted as a parallel randomized controlled intervention trial, initiated by eight weeks rapid weight loss with one of two vlcds, one week of reintroducing regular foods, and 12 weeks with one of two different ad libitum diets; in total 21 weeks. the study will be blinded for the statistician. due to obvious different dietary intakes in the two diets, subjects cannot be blinded and neither the study personnel. as the study includes different dietary recommendations the registered clinical dietician advising the subjects cannot be blinded either. in total 110 overweight and obese volunteers will be included.


Eligibility criteria:
inclusion criteria: * healthy men or women * age, 18-65 years * overweight or grade i-ii obesity (bmi 28-40.0 kg/m2) * provided voluntary written informed consent exclusion criteria (main: * weight changes ± 5% in the last three months * vegetarian, vegan * pregnancy or lactation, pregnancy within the past 12 month or plans to become pregnant during the study * history or diagnosis of diabetes * history or diagnosis of heart, liver or kidney disease * history or diagnosis of eating disorders * chronic diseases e.g. cancer within the past 5 years (except adequately-treated localized basal cell skin cancer) * simultaneous blood donation for other purpose than this study * simultaneous participation in other clinical intervention studies * use of drugs, that in the opinion of the medically responsible investigator, are likely to affect the outcomes of the study * any other condition that judged by the investigator may interfere with the adherence to the study protocol

Keywords: body composition metabolism
knee arthroplasty registry

Conditions: Osteoarthritis, Knee

Summary: objective describe the clinical and demographic characteristics of patients who undergo knee arthroplasty and document post operative outcomes. examine the relationship between processes of care, hospital and surgeon associated outcomes. provide expanded data to characterize existing and evolving practice patterns, delivery of care, and resource utilization in the management of knee arthroplasty patients. analyze and design ancillary studies to address unanswered questions. disseminate findings through publication in peer-reviewed scientific journals.

population: all male and non-pregnant females undergoing knee arthroplasty. study design: prospective, consecutive series on an unlimited number of patients. data collection clinic data: patient demographics- age, weight, height, gender, affected side, co-morbidities, current medications, and contact information knee society score sf-12 evaluation of radiographs- ap, ml, and merchant view preop lab results surgical data: surgical approach asa level size of implants, catalog and lot numbers time of surgery estimated blood loss (ml) length of incision (cm) intraoperative rom any peculiar findings (i.e. heterotopic bone, large osteophytes, etc.) preop lab results postoperative data sf-12 modified knee society score quad strength testing evaluation of radiographs, ap, ml, and merchant view

Eligibility criteria:
inclusion criteria: 1. patient is a male or non-pregnant female over the age of 21. 2. patient requires a knee arthroplasty, revision knee arthroplasty, or unicondylar knee arthroplasty 3. patient has signed and dated an irb approved consent form. 4. patient is able and willing to participate in the study according to the protocol for the full length of expected term of follow-up, and to follow their physician's directions. 5. patient has failed to respond to conservative treatment modalities. exclusion criteria: 1. patient's bone stock is compromised by disease or infection, which cannot provide adequate support and/or fixation to the prosthesis. 2. patient is a prisoner.

Keywords: knee arthroplasty
effect of structured education to decrease blood pressure for hypertension in elderly

Conditions: Hypertension

Summary: there is a structured educational effect on blood pressure reduction in elderly hypertensive patients.

eligibility criteria are men and women over 60 years old and available to participate in the study for 3 months with blood pressure higher than 140/90. exclusion criteria are severe dementia, malignant hypertension, depression outcome measures are systolic and diastolic blood pressure after 3 months administration of structured education once a month.

Eligibility criteria:
inclusion criteria: * subject with age more than 60 years * blood pressure higher than 140/90 exclusion criteria: * severe dementia * depression * malignant hypertension

Keywords: hypertension
cologne placenta cohort (cpc)

Conditions: Obesity, Maternal; Gestational Diabetes Mellitus in Pregnancy

Summary: aim of the study was to determine if signaling pathways in placentas of mothers affected by overweight/obesity or by gestational diabetes are altered compared to placentas of a control group (normal weight, no gestational diabetes). moreover, maternal blood and umbilical cord blood were analysed.


Eligibility criteria:
inclusion criteria: * singleton pregnancy * bmi before pregnancy \>= 18 * with \& without gestational diabetes * c-section at gestational week 35+0 until 41+6 exclusion criteria: * multiple pregnancy * maternal serious internal disease * infections before pregnancy (e.g. hiv, hepatitis b) * pregnancy-associates diseases (e.g. gestoses, androgen insensitivity syndrome)